Publications by authors named "P Alster"
Possible Impact of Peripheral Inflammatory Factors and Interleukin-1β (IL-1β) on Cognitive Functioning in Progressive Supranuclear Palsy-Richardson Syndrome (PSP-RS) and Progressive Supranuclear Palsy-Predominant Parkinsonism (PSP-P).
Int J Mol Sci
December 2024
Progressive supranuclear palsy (PSP) is a tauopathic atypical parkinsonian syndrome. Recent studies suggest that inflammation may play a role in PSP pathogenesis, highlighting markers like the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and cytokines such as IL-1β and IL-6. This study aimed to assess the relationship between peripheral inflammatory markers and psychological abnormalities in PSP-RS and PSP-P patients.
View Article and Find Full Text PDFArticle Synopsis
- - Progressive supranuclear palsy (PSP) is a type of parkinsonism marked by symptoms like eye movement issues, balance problems, and cognitive decline, which complicate its diagnosis and has no effective treatments.
- - PSP is recognized as the second most common neurodegenerative parkinsonism after Parkinson's disease (PD), with symptoms including gait instability and early cognitive changes, differing from PD presentations.
- - The classification of PSP has evolved since its initial description in 1963, leading to better diagnostic criteria in 2017, and emphasizes the importance of assessing quality of life for patients as a basis for further research.
Article Synopsis
- - Atypical parkinsonisms (APs) include symptoms like motor issues, cognitive decline, and autonomic dysfunction, with olfactory loss (OL) being a unique non-motor symptom that may help differentiate APs.
- - Research shows that olfactory loss is most severe in Dementia with Lewy Bodies (DLB), but mild OL may also occur in some patients with Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD), possibly due to abnormal protein deposits in the brain.
- - The review emphasizes the importance of olfactory testing as a quick, non-invasive method for distinguishing APs and understanding their progression, with a call for standardized testing protocols to enhance clinical
Introduction: Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are tauopathic atypical parkinsonisms. Given their overlap in terms of clinical manifestation, there is growing interest in the mechanisms leading to these entities.
Materials And Methods: In total, 71 patients were included in the study, 19 of whom were clinically diagnosed with CBS, 37 with PSP, and 15 with Parkinson's disease (PD).
Atypical parkinsonian syndromes (APSs) are a group of neurodegenerative disorders that differ from idiopathic Parkinson's disease (IPD) in their clinical presentation, underlying pathology, and response to treatment. APSs include conditions such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). These disorders are characterized by a combination of parkinsonian features and additional symptoms, such as autonomic dysfunction, supranuclear gaze palsy, and asymmetric motor symptoms.
View Article and Find Full Text PDF